TW200510356A - Benzoxaepine compounds - Google Patents
Benzoxaepine compoundsInfo
- Publication number
- TW200510356A TW200510356A TW093122662A TW93122662A TW200510356A TW 200510356 A TW200510356 A TW 200510356A TW 093122662 A TW093122662 A TW 093122662A TW 93122662 A TW93122662 A TW 93122662A TW 200510356 A TW200510356 A TW 200510356A
- Authority
- TW
- Taiwan
- Prior art keywords
- optionally substituted
- ring
- bond
- group
- compound
- Prior art date
Links
- LWZYUACNWRVDDJ-UHFFFAOYSA-N 1-benzoxepine Chemical class O1C=CC=CC2=CC=CC=C12 LWZYUACNWRVDDJ-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 108010022535 Farnesyl-Diphosphate Farnesyltransferase Proteins 0.000 abstract 1
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000002947 alkylene group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 125000001183 hydrocarbyl group Chemical group 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 230000000055 hyoplipidemic effect Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D267/02—Seven-membered rings
- C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D267/14—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2003285341 | 2003-08-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW200510356A true TW200510356A (en) | 2005-03-16 |
Family
ID=34113877
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW093122662A TW200510356A (en) | 2003-08-01 | 2004-07-29 | Benzoxaepine compounds |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20080227770A1 (zh) |
| EP (1) | EP1650201A4 (zh) |
| KR (1) | KR20060052906A (zh) |
| CN (1) | CN1832934A (zh) |
| AU (1) | AU2004260757A1 (zh) |
| BR (1) | BRPI0413009A (zh) |
| CA (1) | CA2534464A1 (zh) |
| IL (1) | IL173324A0 (zh) |
| MX (1) | MXPA06001007A (zh) |
| NO (1) | NO20061009L (zh) |
| RU (1) | RU2337100C2 (zh) |
| TW (1) | TW200510356A (zh) |
| WO (1) | WO2005012272A1 (zh) |
| ZA (1) | ZA200600899B (zh) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPWO2006115193A1 (ja) * | 2005-04-22 | 2008-12-18 | 国立大学法人神戸大学 | 黄色腫治療剤 |
| TW200730503A (en) * | 2005-10-21 | 2007-08-16 | Daiichi Seiyaku Co | Tricyclic compound |
| WO2008032696A1 (fr) * | 2006-09-12 | 2008-03-20 | Takeda Pharmaceutical Company Limited | Agent préventif ou thérapeutique pour une maladie respiratoire |
| JP2010150142A (ja) * | 2007-04-25 | 2010-07-08 | Daiichi Sankyo Co Ltd | 三環性ヘテロアリール化合物 |
| WO2010041726A1 (ja) * | 2008-10-10 | 2010-04-15 | 第一三共株式会社 | 置換三環性ヘテロアリール化合物 |
| CN101891639A (zh) * | 2009-05-20 | 2010-11-24 | 上海先导化学有限公司 | 一种制备5-氨基酮戊酸盐酸盐的方法 |
| MY184074A (en) * | 2009-09-28 | 2021-03-17 | Hoffmann La Roche | Benzoxazepin p13k inhibitors compounds and methods of use |
| CN108623555B (zh) * | 2017-03-17 | 2021-07-06 | 中国医学科学院药物研究所 | 一种苯并氧杂䓬类化合物、及其制备方法和药物组合物与用途 |
| GB202213166D0 (en) | 2022-09-08 | 2022-10-26 | Cambridge Entpr Ltd | Novel compounds, compositions and therapeutic uses thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH07267939A (ja) * | 1994-02-09 | 1995-10-17 | Takeda Chem Ind Ltd | 光学活性な４，１−ベンゾオキサゼピン誘導体とその用途 |
| JP3479796B2 (ja) * | 1995-09-13 | 2003-12-15 | 武田薬品工業株式会社 | ベンゾオキサゼピン化合物 |
| EP1097928B1 (en) * | 1995-09-13 | 2008-07-16 | Takeda Pharmaceutical Company Limited | 5-(2,3-Dialkoxyphenyl)-4,1-benzoxazepin-2-ones as anti-hyperlipidemics |
| US5965553A (en) * | 1996-06-20 | 1999-10-12 | Pfizer Inc. | Squalene synthetase inhibitors |
| JP4138299B2 (ja) * | 2000-11-09 | 2008-08-27 | 武田薬品工業株式会社 | 高密度リポタンパク−コレステロール上昇剤 |
| KR20030048465A (ko) * | 2000-11-09 | 2003-06-19 | 다케다 야쿠힌 고교 가부시키가이샤 | 고밀도 지질단백질-콜레스테롤 상승제 |
-
2004
- 2004-07-29 TW TW093122662A patent/TW200510356A/zh unknown
- 2004-07-30 US US10/566,883 patent/US20080227770A1/en not_active Abandoned
- 2004-07-30 CA CA002534464A patent/CA2534464A1/en not_active Abandoned
- 2004-07-30 ZA ZA200600899A patent/ZA200600899B/en unknown
- 2004-07-30 CN CNA2004800222020A patent/CN1832934A/zh active Pending
- 2004-07-30 AU AU2004260757A patent/AU2004260757A1/en not_active Abandoned
- 2004-07-30 BR BRPI0413009-0A patent/BRPI0413009A/pt not_active IP Right Cessation
- 2004-07-30 RU RU2006106281/04A patent/RU2337100C2/ru not_active IP Right Cessation
- 2004-07-30 EP EP04748264A patent/EP1650201A4/en not_active Withdrawn
- 2004-07-30 WO PCT/JP2004/011293 patent/WO2005012272A1/ja active Application Filing
- 2004-07-30 MX MXPA06001007A patent/MXPA06001007A/es not_active Application Discontinuation
- 2004-07-30 KR KR1020067001839A patent/KR20060052906A/ko not_active Withdrawn
-
2006
- 2006-01-24 IL IL173324A patent/IL173324A0/en unknown
- 2006-03-01 NO NO20061009A patent/NO20061009L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2005012272A1 (ja) | 2005-02-10 |
| NO20061009L (no) | 2006-05-02 |
| MXPA06001007A (es) | 2006-04-27 |
| EP1650201A1 (en) | 2006-04-26 |
| CA2534464A1 (en) | 2005-02-10 |
| IL173324A0 (en) | 2006-06-11 |
| AU2004260757A1 (en) | 2005-02-10 |
| BRPI0413009A (pt) | 2006-10-03 |
| ZA200600899B (en) | 2007-04-25 |
| RU2006106281A (ru) | 2006-08-10 |
| RU2337100C2 (ru) | 2008-10-27 |
| KR20060052906A (ko) | 2006-05-19 |
| US20080227770A1 (en) | 2008-09-18 |
| EP1650201A4 (en) | 2009-02-18 |
| CN1832934A (zh) | 2006-09-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| YU101302A (sh) | Derivat benzoilpiridina ili njegova so, fungicid koji ga sadrži u vidu aktivnog sastojka, postupak za njegovu proizvodnju i intermedijer za njegovo dobijanje | |
| HK1099235A1 (en) | Phosphonate analogs of hiv integrase inhibitor compounds hiv | |
| SE0103046D0 (sv) | Kristallin bas av citalopram | |
| EP3321263A3 (en) | Compounds for preparing hepatitis c virus inhibitors | |
| MX2013000295A (es) | Procedimiento de preparacion de un inhibidor especifico de la trombina. | |
| IN2012DN00758A (zh) | ||
| BG105457A (en) | Method for the preparation of citalopram | |
| UA92083C2 (ru) | Азабициклические алкановые производные, замещенные конденсированным бициклогетероциклом | |
| TW200612195A (en) | Oxime derivatives and the use therof as latent acids | |
| WO2007092721A3 (en) | Vitamin d analog: rak, methods and uses thereof | |
| TW200734038A (en) | Novel dispersant and compositions thereof | |
| MX2010002662A (es) | Aminoquinolonas espirociclicas como inhibidores de gsk-3. | |
| NZ605010A (en) | Novel calcium salts of compound as anti-inflammatory, immunomodulatory and anti-proliferatory agents | |
| TW200510356A (en) | Benzoxaepine compounds | |
| SI1753723T1 (sl) | Substituirani kinolinski derivati kot mitotiäśni kinesinski inhibitorji | |
| RS20050241A (en) | Synthesis of thiophenecarboxylic acid esters for the production of ranelic acid salts | |
| AR038624A1 (es) | Un procedimiento para preparar un derivado de fenilalanina e intermediarios del mismo | |
| HK1080088A1 (zh) | 製備c-7取代的5-雄甾烯的方法 | |
| BG107050A (en) | Method for the preparation of citalopram | |
| MXPA04000771A (es) | Metodo para nitracion de compuestos fenolicos. | |
| EP1148783A4 (en) | CONVERSION OF COX INHIBITING, NON COX-2 SELECTIVE INHIBITORS TO DERIVATIVES OF COX-2 SELECTIVE INHIBITORS | |
| HU0004701D0 (zh) | ||
| TW200626533A (en) | Hydroxy-aromatic compound, process for the preparation thereof, and use of the compound | |
| MXPA05003909A (es) | Compuestos de benzopiranona, composiciones de los mismos, y metodos para el tratamiento o prevencion del cancer. | |
| ATE446284T1 (de) | Indolderivate mit einer acetylengruppe als ppar- aktivatoren |